SUMOylation Inhibitor TAK-981 Alleviates Hallmark Features of Preeclampsia Related to High Glucocorticoid Exposure by Inhibiting Placental Oxidative Stress in Rats
Open Access
- 11 April 2026
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 478
Abstract
SUMOylation may be involved in preeclampsia (PE) progression. We aimed to investigate the roles of SUMOylation in PE and its underlying mechanism using animal and cell models. A rat PE model was established by dexamethasone (DEX) treatment from pregnancy day 7.5–17.5. HTR8 and BeWo trophoblasts were used as cell models. Placental RNA-seq analysis coupled with Western blotting showed upregulated SUMOylation in placentas of DEX-treated rats. SUMOylation inhibitor TAK-981 treatment robustly alleviated PE-like features including reduced blood pressure and improved renal injury, fetal weight, spiral artery remodeling and placental blood flow in DEX-treated rats. DEX increased SUMOylation in HTR8 and BeWo cells. TAK-981 reversed DEX-induced dysfunction in HTR8 and BeWo cells, such as migration, invasion and syncytialization. Mass spectrum analysis of SUMO1 immunoprecipitation coupled with functional validation showed that SUMOylated proteins related to oxidative stress caused by DEX were reversed by TAK-981 in cultured trophoblasts. TAK-981 mitigated placental oxidative stress in DEX-treated rats. GEO database combined with Western blotting showed upregulated SUMOylation in human placentas with PE. Our findings indicate that protein SUMOylation is one of the key events in PE, particularly in that associated with high glucocorticoid exposure. Targeting placental SUMOylation might be a promising therapeutic strategy for PE.Keywords
Funding Information
- National Natural Science Foundation of China (82401993)
- National Natural Science Foundation of China (82471711)
- Natural Science Foundation of Hunan Province (2025JJ60674)
- Natural Science Foundation of Changsha City (kq2403011)
- National Postdoctoral Researcher Program (GZC20233154)
This publication has 62 references indexed in Scilit:
- TAK-981 potentiates doxorubicin immunocide in triple-negative breast cancer by IFN I-dependent NK cell stimulationCellular Oncology, 2025
- Pharmacokinetics of betamethasone in pre‐eclampsia: An in vivo and ex vivo studyBritish Journal of Clinical Pharmacology, 2025
- SENP6‐Mediated deSUMOylation of Nrf2 Exacerbates Neuronal Oxidative Stress Following Cerebral Ischemia and Reperfusion InjuryAdvanced Science, 2024
- SUMOylation and DeSUMOylation: Tug of War of Pain SignalingMolecular Neurobiology, 2024
- Thrombospondin‐1 Regulates Trophoblast Necroptosis via NEDD4‐Mediated Ubiquitination of TAK1 in PreeclampsiaAdvanced Science, 2024
- SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac HypertrophyAdvanced Science, 2024
- The Clinical Value of Rodent Models in Understanding Preeclampsia Development and ProgressionCurrent Hypertension Reports, 2023
- Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2022
- Dexamethasone Upregulates the Expression of Aquaporin4 by Increasing SUMOylation in A549 CellsInflammation, 2020
- The requirement of SUMO2/3 for SENP2 mediated extraembryonic and embryonic developmentDevelopmental Dynamics, 2019